Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sarepta Therapeutics (SRPT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Options Traders Expect Huge Moves in Sarepta (SRPT) Stock

Sarepta (SRPT) needs investors to pay close attention to the stock based on moves in the options market lately.

SRPT : 102.29 (+3.55%)
Sarepta Inks Manufacturing Deal for Gene Therapy Program

Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

AGLE : 10.59 (+1.83%)
SRPT : 102.29 (+3.55%)
ANIP : 67.39 (+1.58%)
PFE : 36.36 (+0.55%)
Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene Therapy Development and Commercial Supply

-- The partnership will provide commercial supply for a potential micro-dystrophin gene therapy product launch and other neuromuscular programs in the pipeline --

SRPT : 102.29 (+3.55%)
Sarepta Therapeu Shares Up 24.3% Since SmarTrend's Buy Recommendation (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on April 11th, 2018 at $79.45. In approximately 2 months, Sarepta Therapeu has returned 24.31% as of today's recent price of $98.76.

SRPT : 102.29 (+3.55%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted...

SRPT : 102.29 (+3.55%)
Sarepta Therapeutics to Host R&D Day on Tuesday, June 19, 2018

-- Event to be Webcast Live -

SRPT : 102.29 (+3.55%)
Sarepta Therapeutics Appoints Gilmore O'Neill, M.B., M.M.Sc. as Chief Medical Officer

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today...

SRPT : 102.29 (+3.55%)
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO

The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.

CELG : 78.08 (-0.40%)
SRPT : 102.29 (+3.55%)
VRTX : 155.02 (+0.02%)
GILD : 70.23 (-1.29%)
REGN : 315.30 (-0.12%)
AMGN : 185.01 (-0.42%)
BIIB : 305.03 (-0.21%)
Sarepta Therapeutics to Present at Two Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today...

SRPT : 102.29 (+3.55%)
Wired News - CHMP Adopted Negative Opinion for Sarepta's EXONDYS in Europe to Treat Patients with Duchenne Muscular Dystrophy

Stock Monitor: Versartis Post Earnings Reporting

SRPT : 102.29 (+3.55%)
Watch for Sarepta Therapeu to Potentially Pullback After Gaining 1.98% Yesterday

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $95.21 to a high of $97.94. Yesterday, the shares gained 2.0%, which took the trading range above the 3-day high...

SRPT : 102.29 (+3.55%)
Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit

-- Dr. Rodino-Klapac, a National Institutes of Health Fellow, is a pioneer in the advancement of gene therapy to treat human disease, whose discoveries have advanced six gene therapy programs from bench...

SRPT : 102.29 (+3.55%)
As Anticipated, Sarepta Receives Negative CHMP Opinion for EXONDYS(R) (eteplirsen) to Treat Patients with Duchenne Muscular Dystrophy in Europe

-- Sarepta will seek re-examination of the opinion and request that a Scientific Advisory Group (SAG) be convened --

SRPT : 102.29 (+3.55%)
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, granted...

SRPT : 102.29 (+3.55%)
Here's Why Sarepta is Up More Than 60% So Far This Year

Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

AGLE : 10.59 (+1.83%)
SRPT : 102.29 (+3.55%)
BMRN : 97.60 (+8.47%)
ANIP : 67.39 (+1.58%)
16.6% Return Seen to Date on SmarTrend Sarepta Therapeu Call (SRPT)

SmarTrend identified an Uptrend for Sarepta Therapeu (NASDAQ:SRPT) on April 11th, 2018 at $79.45. In approximately 1 month, Sarepta Therapeu has returned 16.65% as of today's recent price of $92.67.

SRPT : 102.29 (+3.55%)
Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Alnylam Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / May 7, 2018 / U.S. markets rallied on Friday, despite trade uncertainties and weak employment data, as a surge in Apple led to strong gains by the tech sector. The Dow Jones...

SRPT : 102.29 (+3.55%)
Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced the expansion of its partnership with Sarepta Therapeutics, Inc. (NASDAQ: SRPT) to assist clinicians in...

NVTA : 8.12 (+0.37%)
SRPT : 102.29 (+3.55%)
SmarTrend Watching for Potential Pullback in Shares of Sarepta Therapeu After 12.10% Gain

Sarepta Therapeu (NASDAQ:SRPT) traded in a range yesterday that spanned from a low of $76.20 to a high of $89.19. Yesterday, the shares gained 12.1%, which took the trading range above the 3-day high...

SRPT : 102.29 (+3.55%)
Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

PTGX : 7.16 (+1.42%)
LGND : 191.67 (-0.22%)
CATB : 1.34 (-2.90%)
SRPT : 102.29 (+3.55%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD +2.93 , NFLX -0.89 , VLO -1.64 , RL +0.62 , ALGN -3.61
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. December fell to within 1 1/4 cents of the life of contract low in the overnight session. Managed m...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar